Akkeri at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Akkeri takes part in 2 sessions at ACT 2026 in San Antonio. Its sessions cover first-in-human considerations for drugs delivered directly to the brain and spinal cord, and how weight-of-evidence arguments and waivers can stand in for some late-stage nonclinical safety studies.

OrganizationACT 2026 Attendance
akkeri.com
Consultancies
Nonclinical drug development consultancy whose team includes former FDA reviewers, covering cell and gene therapies, oligonucleotides, biologics and small molecules.
Talk
Sun Nov 15
8:45am–9:10am
Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)
CNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)
Translational safety · Neurotoxicology
Talk
Tue Nov 17
10:45am–11:15am
Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)
Applying Weight-of-Evidence and Waivers for Late-Stage Nonclinical Safety Studies (S09-5)
Regulatory

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Akkeri

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction